Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal

Fineline Cube Dec 23, 2025
Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Policy / Regulatory

CDE Reference Standards 101st Batch Seeks Public Feedback

Fineline Cube Dec 23, 2025
Company Drug

Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections

Fineline Cube Dec 23, 2025
Company Drug

3SBio’s rhTPO Wins NMPA Approval for Liver Disease Thrombocytopenia Before Surgery

Fineline Cube Dec 23, 2025
Company Drug

J&J Subsidiary Janssen Wins FDA Approval for Akeega in BRCA-Positive mCRPC Treatment

Fineline Cube Aug 15, 2023

The US Food & Drug Administration (FDA) has granted marketing approval to Johnson & Johnson...

Company Drug

Medivir’s Fostrox in Combination with Lenvima Shows Promise in Phase IIa HCC Trial

Fineline Cube Aug 15, 2023

Sweden-based Medivir (STO: MVIR) has released interim data from a Phase IIa trial evaluating the...

Company Deals

AstraZeneca to Invest Additional USD 250 Million in Qingdao for Aerosol Production Plant

Fineline Cube Aug 15, 2023

UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) is set to invest an additional USD 250...

Company Deals

Eli Lilly Expands Portfolio with Acquisitions of Sigilon Therapeutics and Versanis Bio

Fineline Cube Aug 15, 2023

Eli Lilly (NYSE: LLY) has completed the separate purchases of US compatriots Sigilon Therapeutics (NASDAQ:...

Policy / Regulatory

NHC Addresses Anti-Corruption Efforts in Pharmaceutical Industry Nationwide

Fineline Cube Aug 15, 2023

The National Health Commission (NHC) convened a conference to address questions on the ongoing anti-corruption...

Company Drug

Pfizer’s Elrexfio Earns Accelerated FDA Approval for Relapsed/Refractory Multiple Myeloma

Fineline Cube Aug 15, 2023

This week, Pfizer (NYSE: PFE) received an accelerated approval from the US Food and Drug...

Company Deals

Novartis Acquires Chinook Therapeutics for $3.2 Billion, Eyes Kidney Disease Market

Fineline Cube Aug 14, 2023

Switzerland-based pharmaceutical major Novartis (NYSE: NVS) has successfully completed the scheduled purchase of US-based kidney...

Company Drug

Janssen’s Talvey Receives FDA Accelerated Approval for Relapsed/Refractory Multiple Myeloma

Fineline Cube Aug 14, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) announced last week that it...

Company Deals

Novo Nordisk to Acquire Inversago Pharma in a Deal Valued Up to USD 1.1 Billion

Fineline Cube Aug 14, 2023

Denmark’s leading pharmaceutical company, Novo Nordisk (NYSE: NVO), has reached an agreement to acquire Canada-based...

Company Drug

Telix Pharmaceuticals and Grand Pharma Initiate Phase III Trial for Illucix in China

Fineline Cube Aug 14, 2023

Australian biotechnology company Telix Pharmaceuticals Ltd (ASX: TLX) and its China market partner, Grand Pharmaceutical...

Company Medical Device

Mirxes Holding Company Receives FDA Breakthrough Device Designation for GASTROClea

Fineline Cube Aug 14, 2023

Singapore-based RNA technology company, Mirxes Holding Company Ltd, which specializes in blood-based miRNA test kit...

Policy / Regulatory

China Unveils State Council Measures to Boost Foreign Direct Investment

Fineline Cube Aug 14, 2023

The State Council of China has demonstrated its commitment to encouraging greater foreign investment by...

Company Drug

Bio-Thera Solutions’ BAT8006 Shows Positive Phase I Results in Solid Tumor Treatment

Fineline Cube Aug 14, 2023

China-based Bio-Thera Solutions, Ltd (SHA: 688177) has announced positive Phase I clinical data for BAT8006...

Company Drug

Vcanbio Receives Orphan Drug Designation for VUM02 in Idiopathic Pulmonary Fibrosis Treatment

Fineline Cube Aug 14, 2023

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that it has...

Company Drug

Asieris Pharmaceuticals’ Hexvix Meets Primary Endpoint in Phase III Bladder Cancer Study

Fineline Cube Aug 14, 2023

China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has revealed that a Phase III study...

Company Deals

Eli Lilly Completes Acquisition of Dice Therapeutics for $2.0 Billion

Fineline Cube Aug 14, 2023

Pharmaceutical giant Eli Lilly (NYSE: LLY) has successfully concluded the purchase of US-based Dice Therapeutics...

Company Drug

Sichuan Kelun-Biotech’s SKB264 Achieves Primary Endpoint in Phase III TNBC Study

Fineline Cube Aug 14, 2023

Sichuan Kelun Pharmaceutical Co., Ltd’s innovative drug development subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:...

Company Drug

Huadong Medicine’s HDM3001, a Biosimilar to Stelara, Accepted for Review by NMPA

Fineline Cube Aug 14, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration...

Company Deals

Cascade Pharmaceuticals Secures RMB140 Million in Financing to Advance FXR Agonist Clinical Trials

Fineline Cube Aug 14, 2023

Shanghai-based sino-foreign joint venture, Cascade Pharmaceuticals, Inc., has reportedly raised RMB140 million in a recent...

Company Deals

Migrasome Therapeutics Secures Over RMB100 Million in Angel+ Funding Round

Fineline Cube Aug 14, 2023

Beijing-based biotech startup Migrasome Therapeutics has reported raising upwards of RMB100 million in its angel...

Posts pagination

1 … 424 425 426 … 601

Recent updates

  • Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections
  • Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal
  • 3SBio’s rhTPO Wins NMPA Approval for Liver Disease Thrombocytopenia Before Surgery
  • Gilead’s Seladelpar Wins China Hainan Approval for PBC Treatment
  • Alphamab JSKN003 ADC FDA Breakthrough Therapy Targets Ovarian Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections

Company Deals

Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal

Company Drug

3SBio’s rhTPO Wins NMPA Approval for Liver Disease Thrombocytopenia Before Surgery

Company Drug

Gilead’s Seladelpar Wins China Hainan Approval for PBC Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.